国产创新器械两倍增长，为何仍难迎“创新药时刻”？

Core Insights - The National Medical Products Administration (NMPA) has approved several innovative medical devices, including a first-of-its-kind disposable peripheral vascular thrombectomy catheter, which meets international advanced standards [1] - In 2025, the NMPA announced that 122 products entered the special approval process for innovative medical devices, nearly doubling from 2024 [1][8] - The Chinese innovative medical device sector is poised for a significant breakthrough, similar to the rise of innovative pharmaceuticals in recent years [2] Group 1: Innovative Medical Device Market Trends - The trend of innovative medical device business development (BD) in China is gaining momentum, with domestic companies increasingly collaborating with local innovative device firms and multinational corporations [3] - Major Chinese companies like Yuan Da Pharmaceutical have formed partnerships with various innovative device firms to expand their product lines [4] - Global giants such as Edwards Lifesciences and Johnson & Johnson are collaborating with Chinese innovative device companies, indicating a narrowing gap in innovation and quality [4] Group 2: Approval Statistics and Comparisons - In 2025, 72 innovative medical devices were approved through the special review process, marking a historical high and a continuous growth trend since 2019 [6] - The number of innovative medical devices entering the special review process in 2025 reached 122, a significant increase compared to previous years [8] - The number of second-class innovative medical devices approved by provincial regulatory bodies also saw a substantial increase, with 131 products entering the special approval process in 2025, up over 30% from 2024 [10] Group 3: Challenges and Future Outlook - Despite the progress, the innovative medical device sector faces challenges in replicating the success of innovative pharmaceuticals due to differences in commercialization and development logic [15][16] - The commercialization of innovative devices is more complex and requires ongoing validation in clinical settings, making it harder to achieve rapid market penetration [17] - To enhance the development of innovative medical devices, systemic adjustments are needed, including faster approval processes, supportive payment structures, and international standard recognition [18][19]